<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202917</url>
  </required_header>
  <id_info>
    <org_study_id>E203/2004</org_study_id>
    <secondary_id>IRB Project Nr. 21/2004</secondary_id>
    <secondary_id>HSZ-001</secondary_id>
    <nct_id>NCT00202917</nct_id>
  </id_info>
  <brief_title>Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies</brief_title>
  <official_title>Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the feasibility and Toxicity of allogeneic
      haploidentical hematopoietic cell transplantation with CD3/CD19 depleted stem cells and a
      dose reduced conditioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplantation of a CD3/CD19 depleted stem cell grafts after dose reduced conditioning for
      the treatment of treatment refractory or relapsed hematologic malignancies after preceding
      allogeneic or autologous hematopoietic cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality and Morbidity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term toxicity</measure>
  </secondary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKT-3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD3/CD19 depletion on CliniMACS</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt;60, &gt;18 years

          -  Karnofsky &gt;60%

          -  High risk hematologic malignancy or relapse after preceding auto/allo HCT in patients
             with:

          -  ALL

          -  AML

          -  PNH

          -  MDS (RAEB-t/secondary AML)

          -  NHL

          -  ALL

          -  HD

          -  CML

          -  MM

          -  No HLA-identical MRD or URD if not preceding allo-HCT

          -  Use haploidentical donor with KIR-Mismatch if choice

        Exclusion Criteria:

          -  &lt; 3 months after preceding HCT

          -  Active cerebral seizures

          -  &gt; 30% blasts in BM if ALL/AML/CML-BC

          -  Completely chemo-refractory

          -  Preceding myocardial infarction

          -  Ejection fraction &lt;30 % echocardiography

          -  Creatinine clearance &lt;50 ml/min

          -  Respiratory insufficiency on supplemental O2 or DLCO &lt; 30%

          -  Allergy against murine antibodies

          -  HIV infection

          -  Pregnancy

          -  Unable for informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang A Bethge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tuebingen Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Dresden Medical Center</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Marrow Transplantation</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West German Cancer Center, University of Tuebingen Medical Center</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Klinik f√ºr Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wuerzburg Medical Center</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.onkologie-tuebingen.de</url>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <keyword>haploidentical transplantation</keyword>
  <keyword>immunomagnetic cell sorting</keyword>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <keyword>dose reduced conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

